The US Food and Drug Administration on Monday approved a daily pill version of Novo Nordisk’s weight-loss drug Wegovy, introducing a new option for how patients can take medicines in a class of drugs that has revolutionized obesity treatment.

The drug, which Novo Nordisk calls simply the Wegovy pill, uses the same active ingredient – semaglutide – that powers the original Wegovy, along with its sister drug for diabetes, Ozempic.